Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing.

BACKGROUND: Chronic kidney disease (CKD) results in a dramatic increase in skeletal fracture risk. Bisphosphates (BP) are an effective treatment for reducing fracture risk but they are not recommended in advanced CKD. We have recently shown higher acute skeletal accumulation of fluorescently-tagged...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Bone
Egile Nagusiak: Swallow, Elizabeth A., Aref, Mohammad W., Metzger, Corinne E., Sacks, Spencer, Lehmkuhler, Demi R., Chen, Neal, Hammond, Max A., Territo, Paul R., Nickolas, Thomas L., Moe, Sharon M., Allen, Matthew R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6708715/
https://ncbi.nlm.nih.gov/pubmed/31299384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2019.07.007
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak